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We have constructed a series of point mutations in the highly conserved FLVRES motif of the src homology
2 (SH2) domain of the abl tyrosine kinase. Mutant SH2 domains were expressed in bacteria, and their ability
to bind to tyrosine-phosphorylated proteins was examined in vitro. Three mutants were greatly reduced in their
ability to bind both phosphotyrosine itself and tyrosine-phosphorylated cellular proteins. All of the mutants
that retained activity bound to the same set of tyrosine-phosphorylated proteins as did the wild type, suggesting
that binding specificity was unaffected. These results implicate the FLVRES motif in direct binding to
phosphotyrosine. When the mutant SH2 domains were inserted into an activated abl kinase and expressed in
murine fibroblasts, decreased in vitro phosphotyrosine binding correlated with decreased transforming ability.
This finding implies that SH2-phosphotyrosine interactions are involved in transmission of positive growth
signals by the nonreceptor tyrosine kinases, most likely via the assembly of multiprotein complexes with other
tyrosine-phosphorylated proteins.
The src homology 2 (SH2) domain is an approximately
100-amino-acid region found in a variety of proteins impli-
cated in growth control, including nonreceptor protein-
tyrosine kinases, phospholipase C--y, the ras GTPase activa-
tor protein (GAP), the crk oncogene product, and the 85-kDa
phosphatidylinositol 3-kinase subunit (p85) (reviewed in
reference 29). Because SH2 domains are found in a wide
variety of contexts and are not required for catalytic activity,
it has been suggested that SH2 domains confer a modular
function on the proteins in which they are found (29, 35, 44).
Evidence from a number of groups has suggested that SH2
domains bind with high affinity to tyrosine-phosphorylated
cellular proteins (1, 32-34, 36, 38, 39, 51). It is thought that
the SH2 domains of phospholipase C-y, GAP, and p85
mediate the binding of these proteins to growth factor
receptors of the tyrosine kinase class, which rapidly auto-
phosphorylate on tyrosine upon ligand binding (1, 32, 39;
reviewed in references 29 and 55). While the specific role of
SH2-mediated association with growth factor receptors is
still under investigation, altered access to substrates or
increased enzymatic activity due to phosphorylation by the
associated receptor are likely possibilities (16, 26, 40, 41).
In nonreceptor tyrosine kinases, mutations in the SH2
domain modulate biological activity. In most cases, SH2
mutations decrease the transforming activity of activated
kinases (references 8, 18, 24, 30, and 58 and references
therein), although several point mutations in SH2 have been
shown to activate the transforming potential of normally
nontransforming proto-oncogene products (18, 42). Further-
more, SH2 mutations in nonreceptor tyrosine kinases have
been reported to confer host-dependent transforming activ-
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ity (8, 9, 19, 49, 56) and to generate dominant-negative
inhibitors of transformation (20), suggesting a role for SH2
interactions with cellular factors. The mechanism whereby
SH2 mutations modulate the activity of tyrosine kinase
oncogene products is unclear. While the clearest activity of
SH2 domains is phosphotyrosine binding, it is not obvious
how this property is involved in the regulation of biological
activity. The possibility remains that SH2 domains confer a
crucial function that is independent of phosphotyrosine
binding.
In this work, we have generated a series of conservative
point mutations in the SH2 domain of the abl oncogene
product, a nonreceptor tyrosine kinase (17, 48). We show
that several mutations in the highly conserved FLVRES
motif drastically reduce in vitro binding to phosphotyrosine
itself and to tyrosine-phosphorylated proteins, implicating
this region in binding to phosphotyrosine. Reduced binding
to tyrosine-phosphorylated proteins in vitro correlates with
decreased transforming activity in vivo when the mutations
are present in a retrovirally expressed activated abl protein.
These data suggest that binding to phosphotyrosine is in-
volved in transformation by nonreceptor tyrosine kinases.
MATERIALS AND METHODS
Mutagenesis. The dut ung bacterial strain and protocols
from the Muta-Gene kit (Bio-Rad) were used to generate
oligonucleotide-directed point mutations in the abl SH2
domain. For mutants in the glutathione S-transferase (GST)-
SH2 expression vector, the BamHI-EcoRI fragment from
wild-type pGEX-SH2 (38) was subcloned into M13mpl8,
and mutagenesis was performed on uracil-substituted viral
DNA. Mutant BamHI-EcoRI fragments were excised from
M13 replicative-form DNA and reinserted into pGEX-2T
(52). For SH2 mutations in full-length abl, the 2.5-kbp HincIl
fragment containing the SH2 and catalytic domains of c-abl
was subcloned into pTZ19U (Bio-Rad), and mutagenesis was
performed on uracil-substituted phagemid DNA. Mutant
609
610 MAYER ET AL.
HincIl fragments were subcloned into pPL-AXB-HA (see
below).
Mutagenic primers were 28 to 51 nucleotides in length with
one to three mismatches. All resulting mutants were se-
quenced to verify their structures.
Construction and expression of mutant abl genes. Mutant
SH2 domains were inserted into pPL-AXB-HA, a derivative
of the retroviral expression vector pPL-AXB, which encodes
an SH3-deleted type IV c-abl (21). pPL-/XB-HA differs
from its parental vector by the addition of a C-terminal
epitope tag from the influenza virus HA protein (11; details
to be published elsewhere). pPL-AXB-K290M-HA differs
from pPL-AXB-HA by the presence of a point mutation in
the ATP binding site, changing lysine 290 to methionine (23).
pPL-AXB-HA-derived plasmids were transfected into
NIH 3T3 fibroblasts by calcium phosphate coprecipitation
along with pZAP, which encodes a Moloney murine leuke-
mia virus helper, as described previously (21). Briefly, 10 ,ug
of abl-encoding plasmid and 0.5 ptg of pZAP were mixed in
calcium phosphate buffer, and dilutions of the mixture were
transfected onto duplicate plates. Foci were scored from the
1:5 dilution plates 12 days posttransfection. Three indepen-
dent plasmid isolates were analyzed for the V170L mutant,
two were analyzed for R171K and S173C, and one was
analyzed for the wild type (wt), E172Q, E174Q, and S175C.
For transient transfections, 4 Rg of pPL-AXB-HA-derived
plasmids was transfected by calcium phosphate into subcon-
fluent human 293 cells, and lysates were made 44 h post-
transfection.
Bacterial expression. All SH2 domains were expressed in
Escherichia coli NB42 by using the GEX expression system
and purified by using glutathione-agarose as described pre-
viously (52). To generate cleaved SH2 peptides for nuclear
magnetic resonance (NMR) spectroscopy, bacterial lysates
containing GST-SH2 fusion proteins were incubated with
glutathione-agarose beads (Molecular Probes), and then the
beads were washed with TN buffer (50 mM Tris [pH 8.0], 150
mM NaCl) and incubated at room temperature for 2 h in TN
buffer with 2.5 mM CaCl2 and 125 U of human thrombin
(Calbiochem) per liter of original bacterial culture. The
eluate and wash from the cleaved beads were concentrated
with a Centriprep-10 (Amicon), and contaminating proteins
were removed by gel filtration on Superose-12 (Pharmacia).
Cloning and expression of GAP SH2. The N-terminal SH2
domain of murine GAP was cloned from NIH 3T3 total RNA
by using reverse transcription and polymerase chain reac-
tion. The amplified fragment contained sequences corre-
sponding to amino acids 175 to 280 of human GAP (54) as
well as N-terminal BamHI and C-terminal EcoRI sites in the
proper reading frame and orientation for expression from
pGEX-2T. The amplified fragment was digested with EcoRI
and BamHI and cloned into pGEX-2T, and the resulting
clones were sequenced to confirm their identities. The
murine SH2 sequence encodes a protein that is identical in
amino acid sequence to the published human clone.
SH2 binding assays. Phosphotyrosine-agarose and phos-
phoserine-agarose were made by coupling phosphotyrosine
or phosphoserine (Sigma) to Affi-Gel 15 beads (Bio-Rad)
according to the manufacturer's recommendations. Briefly,
20 mM phosphoamino acids were prepared in 100 mM
morpholine propanesulfonic acid (MOPS; pH 7.5), 50 ,mol
of phosphoamino acid was added per ml of Affi-Gel, and the
mixture was incubated at room temperature for 2 h. To assay
binding of GST-SH2 fusion proteins to phosphotyrosine, 20
,ug of fusion protein in 100 ,ul of phosphate-buffered saline
(PBS) plus 1% Triton X-100 was added to 20 [lI of phos-
phoamino acid-agarose or 10 ,ul of glutathione-agarose bead
slurry (50% beads by volume). The mixture was incubated at
4°C for 40 min, then the beads were quickly washed twice
with 1 ml of cold PBS and resuspended in sample buffer, and
half of the sample was subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (13% poly-
acrylamide gels).
Filter-binding assays were performed with biotinylated
GST-SH2 fusion proteins (1 ,ug/ml) as described previously
(38) except that 1% ovalbumin was used for blocking and
peptide binding. All incubations and washes were carried out
at 4°C, and filters were incubated with biotinylated SH2
peptides overnight. For titration experiments, tyrosine-
phosphorylated proteins were purified from an abl-trans-
formed pre-B cell line (AXB-BM [20a, 21]) by immunoaf-
finity chromatography on monoclonal antibody PY20-
agarose beads as described previously (14, 15). Binding
assays were performed as described above at various GST
fusion peptide concentrations, with the exceptions that the
biotinylated probes were diluted fivefold with unbiotinylated
peptide to decrease their specific activity and dithiothreitol
was present at 10 mM in the blocking and binding reactions.
The GST-SH2 fusion proteins were labeled with biotin as
described previously (38) under identical conditions. To
ensure that labeling efficiencies were similar, the relative
specific activity of the biotinylated probes was assessed by
side-by-side comparison of both the intensity of Coomassie
blue staining and labeling with avidin-conjugated alkaline
phosphatase. In all cases, the specific activities were indis-
tinguishable.
Immunoblotting. Immunoblotting was performed by stan-
dard protocols as described elsewhere (38), using monoclo-
nal antibodies PY20 (15), 19-84 (50), and 12CA5 (11), which
recognize phosphotyrosine, abl protein, and influenza virus
HA protein epitope tag, respectively. Bound antibody was
detected with alkaline phosphatase-conjugated anti-mouse
immunoglobulins.
For coprecipitation experiments, 293 cells were lysed in
Triton X-100 lysis buffer containing 1 mM sodium orthovan-
adate, and equal amounts of protein were immunoprecipi-
tated with polyclonal anti-abl serum pEX-4 (31). Immune
complexes were collected on protein A-Sepharose beads and
washed three times with lysis buffer, and aliquots were
immunoblotted and probed with monoclonal antibody PY20
or 19-84 as described above.
NMR spectroscopy. NMR spectra were acquired on a
General Electric OMEGA 500-MHz NMR system operating
at 500.115 MHz at 25°C. Native samples (see Fig. 6A) were
approximately 1 mM in PBS plus 10% D20. A spectral width
of 7,017.54 Hz was used with a water-presaturating single-
pulse sequence of 1.3-s presaturation and an acquisition time
of 1.17 s in 8,192 data locations for 512 cycles. The wt
sample contained approximately 200 ,iM 3-(trimethylsilyl)-
1-propanesulfonate, whose principal resonance appears at
0.0 ppm in the upper spectrum of Fig. 6A. Spectra were
apodized by applying an exponential function with a line
broadening of 2 Hz. The denatured sample (see Fig. 6B) was
110 ,uM wt abl SH2-6 M guanidinium-HCl in 99.96% D20. A
total of 2,048 scans were acquired with a sweep width of
6,006 Hz. No apodization function was applied.
RESULTS
We have previously shown that the abl SH2 domain, when
expressed in E. coli as a fusion protein with GST, binds with
high affinity to tyrosine-phosphorylated cell proteins (38). To
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FIG. 1. SH2 mutations used in this study. The diagram at the top
is a schematic representation of type IV c-abl protein, showing to
scale the locations of the SH3 and SH2 domains, conserved kinase
catalytic domain, and major nuclear localization signal (K5). Below
is shown the sequence of the abl SH2 domain in the vicinity of the
highly conserved FLVRES motif. Amino acids (a.a.) 170 through
175 were individually mutated to the those shown in the line above
(arrowheads). The consensus sequence consists of amino acids
present in at least 50% of all SH2 domains; X denotes less-
conserved residues.
identify residues critical for phosphotyrosine binding and to
probe the biological relevence of this property to abl gene
function, we generated a series of conservative amino acid
changes within the SH2 domain. We chose to mutate resi-
dues within the FLVRES motif of SH2, because this is the
best-conserved region among all SH2 domains (29). Oligo-
nucleotide-directed mutagenesis was used to create single
amino acid changes designed to maintain the approximate
size and hydrophilicity of the wt residues. The six mutants
used in this study are shown in Fig. 1. These mutations were
initially constructed into the GST expression vector to study
the properties of the isolated, bacterially expressed SH2
domains in vitro.
We first examined whether the mutant SH2 domains
bound to phosphotyrosine itself. We have previously shown
that a fraction of tyrosine-phosphorylated proteins bound to
the wt abl SH2 domain could be eluted with high concentra-
tions of phosphotyrosine (38), suggesting that phosphoty-
rosine is directly involved in binding; other studies, how-
ever, have found no effect of phosphotyrosine (33). When
the bacterially expressed GST-SH2 fusion protein was incu-
bated with agarose beads covalently linked to phosphoty-
rosine, a significant fraction bound to the beads, while none
bound to similar beads linked to phosphoserine (Fig. 2B and
C, lanes 2). GST protein lacking SH2 sequences did not bind
(Fig. 2B, lane 1). These results demonstrate that the abl SH2
domain can bind directly and stably to phosphotyrosine and
not to phosphoserine under these conditions. From experi-
ments in which phenyl phosphate, a phosphotyrosine ana-
log, was used to block association of tyrosine-phosphory-
lated cell proteins with the abi SH2 domain, we estimate the
Ki for phenyl phosphate to be between 1 and 10 mM (not
shown). This low-affinity binding to phosphotyrosine is
probably a -common property of functional SH2 domains,
because we have also observed binding to phosphotyrosine
beads for bacterially expressed src and GAP SH2 domains
(not shown).
When the mutant abl SH2 domains were examined for
phosphotyrosine binding, three of the mutants were indistin-
guishable from wt: V170L, E172Q, and E174Q (by conven-
tion, mutants are designated by wt amino acid, residue
number, and mutant amino acid) (Fig. 2B). Three of the
mutants, R171K, S173C, and S175C, showed no detectable
B
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FIG. 2. Binding of bacterially expressed SH2 domains to phos-
photyrosine-agarose. Purified GST-SH2 fusion proteins were incu-
bated with glutathione-agarose (A), phosphotyrosine-agarose (B) or
phosphoserine-agarose (C), and the bound fraction was separated by
SDS-PAGE and visualized by staining with Coomassie blue. Lanes:
M, molecular weight markers (45, 29, and 18 kDa apparent molec-
ular mass); 1, GST alone; 2, wt abl SH2; 3, V17OL; 4, R171K; 5,
E172Q; 6, S173C; 7, E174Q; 8, S175C.
binding to phosphotyrosine, suggesting that these mutations
affect residues directly involved in interaction with phospho-
tyrosine. The fusion proteins were all present at the same
concentration and could be bound by glutathione agarose
with the same efficiency (Fig. 2A). The arginine at wt
position 171 of abl is absolutely conserved in all known SH2
domains; substitution of lysine at this position (which main-
tains the positive charge) eliminated stable phosphotyrosine
binding, suggesting that the specific structure of this arginine
residue is critical to the binding interaction.
To examine whether the SH2 mutants retained high-
affinity binding to tyrosine-phosphorylated cell proteins, we
used biotinylated GST-SH2 fusion proteins at a low concen-
tration (approximately 25 nM) to bind to total protein from
abl-transformed fibroblasts which had been separated by
SDS-PAGE and transferred to nitrocellulose filters (38).
Consistent with results from binding to phosphotyrosine,
three mutants (V17OL, E172Q, and E174Q) bound to ty-
rosine-phosphorylated proteins as well as did the wt, while
three mutants (R171K, S173C, and S175C) showed no spe-
cific binding (Fig. 3, lanes 1). No changes were seen in the
profile of binding to various tyrosine-phosphorylated pro-
teins for any of the mutants that retained activity; like wt
SH2, these mutants bound well to a subset of tyrosine-
phosphorylated proteins and relatively poorly to others,
such as abl protein itself and a prominent protein of approx-
imately 34 kDa. As is the case with wt SH2, all of the
mutants specifically bound few proteins in lysates from
untransformed 3T3 cells, in which the levels of tyrosine-
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FIG. 3. Binding of biotinylated SH2 domains to tyrosine-phosphorylated cell proteins. Lysates from abl-transformed (lane 1) or
untransformed (lane 2) NIH 3T3 cells were separated by SDS-PAGE and transferred to nitrocellulose. Biotinylated GST-SH2 fusion proteins
were incubated with filters as marked, and bound probe was detected with avidin-conjugated alkaline phosphatase. PY20, a monoclonal
antibody that recognizes phosphotyrosine (aPY), was used to detect total tyrosine-phosphorylated proteins. GEX, GST protein lacking SH2
sequences. Bars represent molecular weight markers (196, 106, 71, 44, and 28 kDa apparent molecular mass).
A more sensitive assay was used to determine whether
any of the mutants retained a low level of residual binding
activity. We purified tyrosine-phosphorylated proteins from
abl-transformed murine bone marrow cells by immunoaf-
finity chromatography, blotted these proteins to nitrocellu-
lose, and assayed binding of the mutant SH2 domains.
Biotinylated SH2 fusion proteins were incubated with filters
at concentrations ranging from 0.1 to 62.5 p.g/ml (approxi-
mately 2.5 nM to 1.5 ,uM). Titration experiments such as
these give an approximate value for the association constant
for various phosphoproteins (the concentration at which
binding is half-maximal). In the case of wt abl SH2, the
apparent half-maximal binding value was less than 100 nM
for some proteins, and the V170L, E172Q, and E174Q
mutants were indistinguishable from wt (Fig. 4). The S173C
and S175C mutants also bound specifically to tyrosine-
phosphorylated proteins, but only when present at high
concentrations. Thus, these mutations decrease the apparent
binding affinity by at least 2 orders of magnitude but do not
completely eliminate binding. Little specific binding was
seen with the R171K mutant, even at the highest concentra-
tion examined.
While several of the SH2 mutants shifted the binding
curve drastically, none of the mutants appeared to signifi-
cantly change the relative affinity for various tyrosine-
phosphorylated proteins. To show that the assay would
detect such differences in binding specificity, we used a
biotinylated GST fusion protein containing the N-terminal
SH2 domain of GAP (54, 57). The profile of phosphoprotein
binding was quite different when GAP was compared with
abl (Fig. 5, lanes 1 to 5; compare with profile of wt abl in Fig.
4). In particular, the apparent affinity for a 68-kDa protein
was much higher for the GAP SH2, while the apparent
affinity for 34- and 36-kDa proteins was somewhat higher for
the abl SH2. This finding is consistent with the results of
Moran et al., who found that in solution, different SH2
domains have different apparent specificities and that the
GAP SH2 has high affinity for a 62-kDa protein (39). In the
concentration range examined, neither the abl or GAP SH2
domain bound to all the tyrosine-phosphorylated proteins
detected by an antiphosphotyrosine antibody (Fig. 5, lane 6).
From this result, we conclude that the filter-binding assay is
able to detect relative affinity differences and that the
FLVRES mutations most likely affect only binding to phos-
photyrosine and not the interactions that determine the
profile of relative binding to specific tyrosine-phosphory-
lated proteins.
A potential pitfall of mutagenesis experiments is that even
conservative amino acid changes can have global effects on
protein conformation, leading to incorrectly folded or un-
folded mutant proteins. All of the bacterially expressed SH2
mutants used in this study were as soluble as wt, suggesting
that there were no gross abnormalities in folded structure (in
contrast, several mutant abl SH2 domains with more drastic
alterations were clearly less soluble than wt [37a]). NMR
spectroscopy is a very sensitive probe for protein conforma-
tion (59). We therefore prepared wt and R171K mutant
fusion proteins, cleaved them from the GST fusion partner,
purified the SH2 domains to homogeneity, and obtained
one-dimensional NMR spectra. The upfield portions of the
two spectra were virtually superimposable, with only a few
minor differences observed in the chemical shifts (Fig. 6A).
This region of the NMR spectrum contains resonances from
methyl and other aliphatic protons, which are normally
found in the hydrophobic core of the polypeptide; their shifts
are perturbed by the ring current effects of internalized
aromatic residues. Any major change in folded structure
would be expected to cause drastic changes in the spectrum.
The similarity of the two spectra in this upfield fingerprint
region demonstrates that the R171K mutant has a folded
structure similar to that of the wt SH2 domain. To give a
sense of the magnitude of changes in the NMR spectrum
induced by unfolding, we also present the spectrum of the wt
abl SH2 domain in 6 M guanidinium hydrochloride. As seen
in Fig. 6B, many of the dispersed signals of the spectrum are
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FIG. 4. Binding of mutant SH2 domains to purified tyrosine-phosphorylated proteins. Tyrosine-phosphorylated proteins were purified
from abl-transformed murine bone marrow cells, separated by SDS-PAGE, and blotted to identical nitrocellulose strips. Strips were incubated
with biotinylated GST-SH2 fusion proteins as marked, at concentrations of 0.1 ,ug/ml (lane 1), 0.5 ,ug/ml (lane 2), 2.5 ,ug/ml (lane 3), 12.5 p.g/ml
(lane 4), or 62.5 p,g/ml (lane 5), and detected with avidin-conjugated alkaline phosphatase. Markers are as in Fig. 3.
native spectrum, even though the samples are identical in
primary structure. The diminished phosphotyrosine binding
of the mutant is therefore probably not due to a substantial
disruption of protein conformation but is more likely due to
specific alterations in the binding region.
To examine the role of phosphotyrosine binding in the
transforming activity of abl, the various FLVRES point
mutations were constructed into an activated abl gene. A
type IV c-abl gene containing a deletion of the SH3 domain
was used, which is highly transforming for both fibroblasts
and pre-B cells (21). An epitope tag from influenza virus was
appended to the C terminus to facilitate detection of the
protein with a highly specific monoclonal antibody (11); the
epitope tag does not significantly affect transforming activity
(20a). The various mutant abl genes were inserted into a
retroviral expression vector and transfected into NIH 3T3
fibroblasts along with helper virus. The three mutants con-
taining SH2 domains with wt phosphotyrosine-binding activ-
ity in vitro were similar to wt in focus-forming activity
(decreased by less than twofold relative to wt), while the
mutants containing SH2 domains impaired in phosphoty-
rosine binding had significantly decreased focus-forming
activity (35-, 10-, and 4-fold relative to wt for R171K, S173C,
and S175C, respectively) (Table 1). The relative decrease in
transforming activity roughly paralleled the decrease in in
vitro phosphotyrosine binding, in that little or no binding
was seen with R171K, while some binding was evident with
S173C and S175C, especially the latter (Fig. 4). The few
transformed foci from the R171K mutant were smaller and
more fusiform than wt foci and were difficult to establish as
cell lines. Cells transformed by mutant S173C were also
morphologically distinguishable from wt, while the other
mutants gave foci with morphology and growth properties
similar to those of wt (not shown). All of the mutants had
greater transforming activity than normal (unactivated)
c-abl, which has undetectable focus-forming activity in this
assay (Table 1).
A possible explanation for the decreased transforming
activity of the abl genes containing mutant SH2 domains
could be a defect in protein production. Plates transfected
with the various mutants were maintained for 25 days to
allow viral spread, and lysates were prepared and immuno-
blotted to detect abl proteins. Roughly comparable amounts
of the mutant proteins were detected (Fig. 7; compare lanes
1 to 6 with lanes 7), using antibodies that recognize the
influenza virus epitope tag (Fig. 7A) or abl protein (Fig. 7B).
In vitro kinase assays performed on immunoprecipitated
mutant proteins demonstrated that all mutants also had
similar kinase activities (data not shown).
If the defect in the less-transforming mutants was a failure
to associate with tyrosine-phosphorylated proteins, this dif-
ference should be apparent in an analysis of proteins bound
VOL. 12, 1992
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FIG. 5. Phosphoprotein binding profile of the GAP SH2 domain.
Strips identical to those shown in Fig. 4 were prepared and probed
with biotinylated GST-GAP N-terminal SH2 under conditions iden-
tical to those used for Fig. 4. GAP SH2 was used at 0.1, 0.5, 2.5,
12.5, and 62.5 ,ug/ml in lanes 1 to 5, respectively. Lane 6, immuno-
blot with phosphotyrosine-specific monoclonal antibody PY20.
Markers are as in Fig. 3.
to the mutant abl proteins. To address this matter, we
expressed the mutants in human 293 cells in a transient assay
system. This approach allows a large population of cells
expressing the mutants to be examined without the compli-
cating effects of positive and negative selection involved in
isolating clonal cell lines. abl proteins were immunoprecip-
itated from 293 cell lysates with a polyclonal anti-abl serum,
and aliquots of the washed immunoprecipitates were immu-
noblotted with antiphosphotyrosine (Fig. 8A) or monoclonal
anti-abl (Fig. 8B). Previous work in this laboratory has
demonstrated that transforming abl proteins coimmunopre-
cipitate with a 65- to 68-kDa protein that comigrates with the
major tyrosine-phosphorylated protein that associates with
GAP (10, 39, 50a). This protein also coimmunoprecipitated
with the FLVR mutants that retain in vitro binding to
phosphotyrosine (Fig. 8A, lanes 3, 5, and 7). By contrast,
those mutants with decreased in vitro binding coimmunopre-
cipitated little if any 65- to 68-kDa protein (Fig. 8A, lanes 4,
6, and 8). Blotting with abl-specific antiserum showed that
similar levels of mutant abi proteins were present in all
immunoprecipitates (Fig. 8B). Blotting of whole cell lysates
with antiphosphotyrosine showed that phosphotyrosine lev-
els were increased in 293 cells expressing all FLVR mutants
(data not shown). A kinase-inactive abl mutant with a point
mutation in the ATP binding site also coimmunoprecipitated
a small amount of 65- to 68-kDa protein (Fig. 6A, lane 2),
presumably via its intact SH2 domain, even in the absence of
increased phosphotyrosine due to abl kinase activity.
DISCUSSION
We have demonstrated in this study that point mutations
in the highly conserved FLVRES motif of the abl SH2
domain drastically decreased SH2 binding to phosphoty-
rosine and tyrosine-phosphorylated proteins in vitro. De-
creased binding was paralleled by a coordinate decrease in
the transforming activity of activated abl genes containing
the SH2 mutations. Using NMR spectroscopy, we were able
to show that the folded structure of the mutant most im-
paired in its ability to bind phosphotyrosine was not drasti-
cally affected by the mutation. These results strongly impli-
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FIG. 6. One-dimensional NMR spectra of purified wt abl and
R171K mutant SH2 domains. The upfield fingerprint region of each
spectrum is shown. (A) Spectra of native wt and R171K mutant SH2
domains in PBS. The sharp peak at 0.0 ppm in the wt spectrum is the
3-(trimethylsilyl)-1-propanesulfonate chemical shift standard. (B)
Spectrum of the wt SH2 domain in 6 M guanidinium hydrochloride.
function of SH2 domains, in modulation of the biological
activity of nonreceptor tyrosine kinases. Our results also
suggest that in vitro studies with isolated, bacterially ex-
pressed SH2 domains, which are easily manipulated and
whose binding interactions can be analyzed quantitatively,
can be extrapolated to the behavior of SH2 domains in intact
proteins.
The region of the SH2 domain that we chose to mutate, the
FLVRES motif, is very highly conserved among all SH2
domains (over 30 to date [29]). We propose that SH2 binding
to tyrosine-phosphorylated peptides involves two distinct
interactions: a low-affinity binding to phosphotyrosine itself,
mediated at least in part by the FLVRES motif, and subse-
quent interaction with peptide residues surrounding the
phosphotyrosine, in which nonconserved SH2 amino acids
confer high-affinity binding. We have found that SH2 do-
mains interact with phosphotyrosine and phenyl phosphate
MOL. CELL. BIOL.
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TABLE 1. Properties of abl SH2 mutants
Mutant Phosphotyrosine Phosphoprotein Transformingbindinge bindingb activityc
Wtd + + 2,310 (1)
V170L + + 1,350 (1.7)
R171K - - 66 (35)
E172Q + + 1,286 (1.8)
S173C - +/- 225 (10.3)
E174Q + + 1,425 (1.6)
S175C - +/- 563 (4.2)
c-able + + <1 (>2,000)
a Binding of purified GST-SH2 fusion protein to phosphotyrosine-agarose.
b Binding of biotinylated GST-SH2 fusion protein to purified tyrosine-
phosphorylated cell proteins in a filter-binding assay.
c Number of morphologically transformed foci per dish scored 12 days
posttransfection; fold decrease relative to the activated abl gene with the wt
SH2 domain is given in parentheses.
d Activated abl containing an SH3 deletion and C-terminal influenza virus
epitope tag (see text).
I Normal type IV c-abl.
directly, but that the apparent dissociation constant for
phenyl phosphate is in the millimolar range (Fig. 2 and data
not shown). In other experiments, we have found a similar
low affinity for a nonspecific tyrosine-phosphorylated pep-
tide (not shown). The affinity for some tyrosine-phosphory-
lated proteins is much higher; binding of abl or GAP SH2
domains to specific tyrosine-phosphorylated proteins on
filters (Fig. 4 and 5) or to autophosphorylated epidermal
growth factor receptor in a solid-phase enzyme-linked im-
munosorbent assay (2) give apparent half-maximal binding
values of 1 to 10 nM for some binding sites. We have not
observed binding of SH2 domains to unphosphorylated
proteins, suggesting that the low-affinity interaction with
phosphotyrosine is required to initially position the two
proteins so that contacts conferring high-affinity binding can
form. However, Pendergast et al. have found recently that
the abl SH2 domain binds with high affinity in vitro to a
region of the BCR protein, which is fused to abl via
chromosomal translocation in some human leukemias (45).
Binding occurred in the absence of detectable phosphoty-
rosine on the BCR protein but was shown to be dependent
on phosphorylation. It will be of interest to determine
whether the FLVR mutations described here, which disrupt
phosphotyrosine-dependent binding, also disrupt interaction
with BCR.
An important implication of this work is that data demon-
strating the binding of SH2 domains to specific tyrosine-
phosphorylated proteins must be evaluated critically. Be-
cause SH2 domains can bind to phosphotyrosine itself, albeit
with low affinity, it follows that any SH2 domain has the
potential to bind to any tyrosine-phosphorylated protein if
the concentrations are high enough. Titration experiments
on nitrocellulose filters (Fig. 4 and 5) show that binding is
relatively specific at low SH2 concentrations, with a wider
range of phosphoproteins binding at higher SH2 concentra-
tions. The local concentration of SH2 domains and tyrosine-
phosphorylated proteins, coupled with the relative affinities
of the SH2 domains for various proteins, will determine what
interactions are kinetically relevant in vivo. Furthermore,
the accessibility and orientation of SH2 domains, which
could be sequestered in intramolecular interactions, may be
important.
The properties of the FLVRES mutants reported here
provide clues to the nature of the SH2-phosphotyrosine
binding interaction. The observation that replacement of the
invariant arginine at position 171 drastically diminishes
phosphotyrosine binding suggests an important role for this
residue. Positive charges on the SH2 domain might be
expected to interact electrostatically with the negatively
charged phosphate group. While the R171K mutation main-
tains the positive charge, the specific orientation or charge
distribution of arginine is apparently important for stable
binding. The abolition of activity on substitution of arginine
by lysine has been observed in several other systems, most
recently RNA recognition (4). Others have noted that there
are two other relatively invariant basic amino acids in the
SH2 domain, corresponding to arginine 153 and histidine 192
of abl, which might also be involved in phosphate binding
(29). In the crk oncogene product (which does not itself
encode a tyrosine kinase domain), mutation of the FLVRES
arginine or the invariant histidine abolished transforming
activity and decreased binding to tyrosine-phosphorylated
proteins (34, 37).
We have shown that for activated abl kinase, transforming
activity correlates with the phosphotyrosine-binding capac-
ity of the SH2 domain that it encodes. Our results are
generally consistent with previous observations in which
SH2 mutations in src and fps decreased the transforming
activity of the activated kinases (8, 18, 24, 30, 58). We
cannot conclude that phosphotyrosine binding is absolutely
required for transformation by abl because the R171K mu-
tant retains a low level of morphological transforming activ-
ity. In the case of src and fps, it has been clearly shown that
deletions spanning the FLVRES motif decrease but do not
necessarily abolish transforming activity (3, 8, 27, 30, 43,
58). It is possible that there are multiple modes of transfor-
mation by tyrosine kinases, a major subset of which are
dependent on SH2-phosphotyrosine interactions.
Previous studies of mutations in the SH2 domains of
A
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FIG. 7. Expression of abl proteins with mutant SH2 domains.
Lysates were prepared from NIH 3T3 cells transfected with retro-
viral vectors containing activated abl genes harboring SH2 point
mutations. Total cell protein (50 ,ug per lane) was immunoblotted
and detected with monoclonal antibody 12CA5 to the influenza virus
epitope present on the abl protein (A) or monoclonal 19-84, which
recognizes abl protein itself (B). Arrowheads denotes positions of
abl-specific bands. Lanes: 1, V17OL; 2, R171K; 3, E172Q; 4, S173C;
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FIG. 8. Coimmunoprecipitation of tyrosine-phosphorylated proteins with abl SH2 mutants. One milligram of lysate from transiently
transfected 293 cells was immunoprecipitated with polyclonal abl antiserum (pEX-4), and aliquots of washed immunoprecipitates were
immunoblotted with monoclonal antiphosphotyrosine antibody PY20 (A) or anti-abl antibody 19-84 (B). Gels were 10% (A) and 7.5% (B)
acrylamide. Lanes: 1, wt activated abl; 2, K290M kinase-defective mutant; 3, V17OL; 4, R171K; 5, E172Q; 6, S173C; 7, E174Q; 8, S175C;
9, mock transfected. Arrow in panel A indicates major coprecipitating phosphoprotein. Bars represent molecular weight markers (in panel A,
196, 106, 71, and 44 kDa apparent molecular mass; in panel B, 196, 106, and 71 kDa).
tyrosine kinase oncogenes have been complicated by a lack
of data about the specific effects of the mutations. Several
mutations of src and fps in the vicinity of the FLVRES
sequence confer interesting properties, but it is not known
whether these mutations diminish phosphotyrosine binding,
alter other SH2-protein interactions, or result in global
conformation changes. For example, a mutation in the src
SH2 domain changing the invariant arginine (corresponding
to position 171 in abi) to leucine activates the transforming
potential of c-src in chicken cells, while it confers on
activated c-src a host-dependent transformation phenotype
and the ability to suppress transformation of mouse cells by
a second activated src gene (18-20). It would be useful to
determine the extent to which this mutation abrogates bind-
ing of the src SH2 domain to tyrosine-phosphorylated pro-
teins.
The apparent requirement for phosphotyrosine binding for
full transforming activity by abl presents a paradox. The
implication of our results is that it is important for the
nonreceptor tyrosine kinases to bind to the products of their
own catalytic activity. This is inconsistent with the tradi-
tional view of enzymes, in which affinity for the reaction
product is low and turnover is high. A further complication
is that transformation is clearly not the physiological role for
the normal proto-oncogene products, so the function of the
SH2 domain in oncogenic variants may be quite different
from its function in the normal nonreceptor tyrosine kinases.
For example, it has been suggested that SH2 domains could
regulate catalytic activity by interaction with regulatory
phosphorylation sites on the kinases themselves (5, 29, 30,
42). For v-src and activated abl, this is clearly not the case,
because the major sites of tyrosine autophosphorylation can
be eliminated without greatly diminishing transforming ac-
tivity (6, 22, 53). But because SH2 mutations have been
shown, in contrast, to partially activate the transforming
activity of c-src (18, 42), it is possible that intramolecular
binding is in some cases a normal role for SH2 domains.
Consistent with this, in weakly activated c-src variants,
phosphorylation of a catalytic site tyrosine plays a positive
role in transforming activity (28, 46).
A potential role for SH2 domains in transformation is in
localizing the active kinase to a specific subcellular compart-
ment or multiprotein complex. N-terminal myristoylation of
the src or abl oncogene product is in most cases essential for
transforming activity, even though the nonmyristoylated
kinases retain high catalytic activity (6, 21, 23, 25). This
implies that localization plays a critical role in the transform-
ing activity of activated nonreceptor kinases. Once directed
to the membrane by the myristoylated N terminus, the
activated kinases might phosphorylate membrane-associated
substrates and subsequently bind tightly to them via the SH2
domain; assembly of this complex would facilitate the trans-
mission of positive growth signals. Consistent with this
view, it has been shown that an intact SH2 domain is
required for association of v-src protein with the detergent-
insoluble matrix, the p85 phosphatidylinositol kinase sub-
unit, and an unidentified 130-kDa protein (12, 13, 47).
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